TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07182149: A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Sponsor: Normunity AccelCo, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,073,456

Rescue Site Savings

+$1,382,304

Unlock Full NCT07182149 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07182149 Rescue Dossier →